Warning letter
Vitti Labs, LLC: warning letter of Jul 28, 2022
FDA warning letter 627699 · Office of Biological Products Operations – Division 2
Key facts
| Reference number | 627699 |
|---|---|
| Company | Vitti Labs, LLC |
| Subject | Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps) |
| Issue date | Jul 28, 2022 |
| Posted date | Aug 9, 2022 |
| Issuing office | Office of Biological Products Operations – Division 2 |
| Product type | Biologics |
| CFR sections cited | 1271.10(a)(1), 1271.3(d), 312, 211.42(c)(10)(i), 211.84(a), 211.100(a), 211.113(b), 211.160(b), 211.166(a), 1271, 1271.15, 1271.3(c) and 3 more |
| Inspection city | Liberty |
| Inspection ZIP | 64068 |
| Inspection start date | Dec 6, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: